The Convergence of Science and Hope

Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. The Company has developed a pipeline of products based on its proprietary Arcelis technology platform.

View the Arcelis Platform

hp_adapt_its_personal

Argos in The News

Argos Therapeutics to Present at the 21st Annual BioCentury NewsMakers Conference
Read more

Enrollment in Argos Therapeutics' Pivotal Phase III ADAPT Trial of AGS-003 for Metastatic Renal Cell Carcinoma Surpasses Fifty Percent
Read more

Argos Announces Issuance of Arcelis(R) Technology Platform Patent
Read more

> More News & Events Here.

1999

When Our Company Was Founded

2006

First Arcelis product (AGS-003) clinical trial initiated in mRCC

2013

Phase 3 mRCC ADAPT Study Launched

180

Newly diagnosed RCC patients daily in the US, of which ~ 30 will present with stage IV or metastatic RCC